Edition:
India

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

6.05USD
2:29am IST
Change (% chg)

$0.35 (+6.14%)
Prev Close
$5.70
Open
$5.75
Day's High
$6.10
Day's Low
$5.75
Volume
47,520
Avg. Vol
46,054
52-wk High
$14.00
52-wk Low
$4.90

Select another date:

Mon, Nov 6 2017

BRIEF-Minerva Neurosciences reports Q3 loss per share $0.28

* Minerva Neurosciences Inc reports third quarter 2017 financial results and business updates

BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant

* Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant (min-202) as adjunctive therapy in patients with major depressive disorder

BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant

* Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant (MIN-202) as adjunctive therapy in patients with major depressive disorder

BRIEF-Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen

* Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen

BRIEF-Minerva Neurosciences Q2 loss per share $0.27

* Minerva Neurosciences reports second quarter 2017 financial results and business updates

BRIEF-American Journal of Psychiatry publishes Minerva Neurosciences' MIN-101 Phase 2b trial results

* American Journal of Psychiatry publishes Minerva Neurosciences' MIN-101 Phase 2b trial results for treatment of negative symptoms in Schizophrenia

BRIEF-Minerva Neurosciences announces departure of directors

* Announced resignation of two members of its board of directors, Michele Ollier and Nico Vandervelpen

BRIEF-Minerva Neurosciences announces departure of directors

* Minerva Neurosciences announces departure of directors Source text for Eikon: Further company coverage:

BRIEF-Minerva Neurosciences prices 5 mln common shares at $7.75 per share

* Minerva neurosciences announces pricing of public offering of common stock

BRIEF-Minerva announces completion of bridging study to select improved formulation of MIN-101 for use in phase 3 trial for the treatment of negative symptoms in patients with schizophrenia

* Minerva announces completion of bridging study to select improved formulation of MIN-101 for use in phase 3 trial for the treatment of negative symptoms in patients with schizophrenia

Select another date: